PubRank

Akin Akinc

Author PubWeight™ 62.24‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004 12.75
2 RNAi-mediated gene silencing in non-human primates. Nature 2006 7.60
3 Rational design of cationic lipids for siRNA delivery. Nat Biotechnol 2010 4.97
4 Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci U S A 2008 4.57
5 Lipid-like materials for low-dose, in vivo gene silencing. Proc Natl Acad Sci U S A 2010 4.25
6 Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape. Nat Biotechnol 2013 2.81
7 Structure/property studies of polymeric gene delivery using a library of poly(beta-amino esters). Mol Ther 2005 1.87
8 Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew Chem Int Ed Engl 2012 1.87
9 A polymer library approach to suicide gene therapy for cancer. Proc Natl Acad Sci U S A 2004 1.79
10 Effective RNAi-mediated gene silencing without interruption of the endogenous microRNA pathway. Nature 2007 1.66
11 Treatment of erythropoietin deficiency in mice with systemically administered siRNA. Blood 2012 1.64
12 Heme oxygenase-1 is an anti-inflammatory host factor that promotes murine plasmodium liver infection. Cell Host Microbe 2008 1.62
13 Host scavenger receptor SR-BI plays a dual role in the establishment of malaria parasite liver infection. Cell Host Microbe 2008 1.50
14 Gene silencing activity of siRNAs with a ribo-difluorotoluyl nucleotide. ACS Chem Biol 2006 1.33
15 Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J Am Chem Soc 2014 1.31
16 Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates. Proc Natl Acad Sci U S A 2014 1.30
17 Systemic RNAi-mediated Gene Silencing in Nonhuman Primate and Rodent Myeloid Cells. Mol Ther Nucleic Acids 2012 1.24
18 Influence of cationic lipid composition on gene silencing properties of lipid nanoparticle formulations of siRNA in antigen-presenting cells. Mol Ther 2011 1.23
19 Unique gene-silencing and structural properties of 2'-fluoro-modified siRNAs. Angew Chem Int Ed Engl 2011 1.20
20 Combinatorial approach to determine functional group effects on lipidoid-mediated siRNA delivery. Bioconjug Chem 2010 1.11
21 Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics. Mol Ther 2013 1.11
22 Delivering silence: advancements in developing siRNA therapeutics. Curr Opin Drug Discov Devel 2008 1.10
23 Comprehensive evaluation of canonical versus Dicer-substrate siRNA in vitro and in vivo. RNA 2012 0.98
24 In vivo quantification of formulated and chemically modified small interfering RNA by heating-in-Triton quantitative reverse transcription polymerase chain reaction (HIT qRT-PCR). Silence 2010 0.96
25 Assessing siRNA pharmacodynamics in a luciferase-expressing mouse. Mol Ther 2008 0.91
26 CSF transthyretin neuroprotection in a mouse model of brain ischemia. J Neurochem 2010 0.90